Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506249 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP2A6CHUKCSNK1A1CSNK1D | |
| SCHEMBL31322047 | 0.76 | GRM5 (0.44) | ALDH1A1CYP2A6CSNK1A1CSNK1DGSK3B | |
| SCHEMBL7720311 | 0.76 | CYP2A6 (0.48) | ALDH1A1CYP2A6CHUKL3MBTL1MEN1 | |
| SCHEMBL13074276 | 0.74 | CA2 (0.43) | ALDH1A1CYP2A6CHUKL3MBTL1MEN1 | |
| SCHEMBL1102316 | 0.71 | PDE5A (0.51) | ALDH1A1CHUKPDE5ACA1CA2 | |
| SCHEMBL31719497 | 0.71 | PDE5A (0.51) | ALDH1A1CHUKPDE5ACA1CA2 | |
| SCHEMBL20116880 | 0.70 | CYP1A2 (0.39) | ALDH1A1CYP2A6L3MBTL1 | |
| SCHEMBL11986226 | 0.69 | GRM2 (0.38) | ALDH1A1CYP2A6CSNK1A1CSNK1DGSK3B | |
| SCHEMBL10164899 | 0.69 | G6PD (0.38) | ALDH1A1CYP2A6CHUKCASP3 | |
| SCHEMBL22549000 | 0.69 | IRAK4 (0.50) | ALDH1A1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| CN-110099898-B | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| EP-3529245-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| CN-110099898-A | compound and use thereof | 优曼尼蒂治疗公司 | 2019-08-06 | — | — | CN | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885CYP2A6 1182/4885CHUK 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.